184 related articles for article (PubMed ID: 20053767)
1. Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program.
Houghton PJ; Morton CL; Gorlick R; Lock RB; Carol H; Reynolds CP; Kang MH; Maris JM; Keir ST; Kolb EA; Wu J; Wozniak AW; Billups CA; Rubinstein L; Smith MA
Mol Cancer Ther; 2010 Jan; 9(1):101-12. PubMed ID: 20053767
[TBL] [Abstract][Full Text] [Related]
2. Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program.
Morton CL; Maris JM; Keir ST; Gorlick R; Kolb EA; Billups CA; Wu J; Smith MA; Houghton PJ
Pediatr Blood Cancer; 2012 Apr; 58(4):566-71. PubMed ID: 21538824
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of patritumab with or without erlotinib in combination with standard cytotoxic agents against pediatric sarcoma xenograft models.
Bandyopadhyay A; Favours E; Phelps DA; Pozo VD; Ghilu S; Kurmashev D; Michalek J; Trevino A; Guttridge D; London C; Hirotani K; Zhang L; Kurmasheva RT; Houghton PJ
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 29080385
[TBL] [Abstract][Full Text] [Related]
4. mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo.
Cejka D; Preusser M; Fuereder T; Sieghart W; Werzowa J; Strommer S; Wacheck V
Anticancer Res; 2008; 28(6A):3801-8. PubMed ID: 19189667
[TBL] [Abstract][Full Text] [Related]
5. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program.
Houghton PJ; Morton CL; Kolb EA; Gorlick R; Lock R; Carol H; Reynolds CP; Maris JM; Keir ST; Billups CA; Smith MA
Pediatr Blood Cancer; 2008 Apr; 50(4):799-805. PubMed ID: 17635004
[TBL] [Abstract][Full Text] [Related]
6. The pediatric preclinical testing program: description of models and early testing results.
Houghton PJ; Morton CL; Tucker C; Payne D; Favours E; Cole C; Gorlick R; Kolb EA; Zhang W; Lock R; Carol H; Tajbakhsh M; Reynolds CP; Maris JM; Courtright J; Keir ST; Friedman HS; Stopford C; Zeidner J; Wu J; Liu T; Billups CA; Khan J; Ansher S; Zhang J; Smith MA
Pediatr Blood Cancer; 2007 Dec; 49(7):928-40. PubMed ID: 17066459
[TBL] [Abstract][Full Text] [Related]
7. Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program.
Kolb EA; Gorlick R; Maris JM; Keir ST; Morton CL; Wu J; Wozniak AW; Smith MA; Houghton PJ
Pediatr Blood Cancer; 2012 May; 58(5):729-35. PubMed ID: 21630428
[TBL] [Abstract][Full Text] [Related]
8. In vivo evaluation of the EZH2 inhibitor (EPZ011989) alone or in combination with standard of care cytotoxic agents against pediatric malignant rhabdoid tumor preclinical models-A report from the Pediatric Preclinical Testing Consortium.
Kurmasheva RT; Erickson SW; Earley E; Smith MA; Houghton PJ
Pediatr Blood Cancer; 2021 Feb; 68(2):e28772. PubMed ID: 33089597
[TBL] [Abstract][Full Text] [Related]
9. Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program.
Carol H; Lock R; Houghton PJ; Morton CL; Kolb EA; Gorlick R; Reynolds CP; Maris JM; Keir ST; Billups CA; Smith MA
Pediatr Blood Cancer; 2009 Dec; 53(7):1255-63. PubMed ID: 19554570
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy.
Geoerger B; Kerr K; Tang CB; Fung KM; Powell B; Sutton LN; Phillips PC; Janss AJ
Cancer Res; 2001 Feb; 61(4):1527-32. PubMed ID: 11245461
[TBL] [Abstract][Full Text] [Related]
11. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.
Kurmasheva RT; Dudkin L; Billups C; Debelenko LV; Morton CL; Houghton PJ
Cancer Res; 2009 Oct; 69(19):7662-71. PubMed ID: 19789339
[TBL] [Abstract][Full Text] [Related]
12. National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.
Kang MH; Smith MA; Morton CL; Keshelava N; Houghton PJ; Reynolds CP
Pediatr Blood Cancer; 2011 Feb; 56(2):239-49. PubMed ID: 20922763
[TBL] [Abstract][Full Text] [Related]
13. Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program.
Kurmasheva RT; Kurmashev D; Reynolds CP; Kang M; Wu J; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28921800
[TBL] [Abstract][Full Text] [Related]
14. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).
Maris JM; Morton CL; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Reynolds CP; Kang MH; Wu J; Smith MA; Houghton PJ
Pediatr Blood Cancer; 2010 Jul; 55(1):26-34. PubMed ID: 20108338
[TBL] [Abstract][Full Text] [Related]
15. Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.
Reynolds CP; Kang MH; Carol H; Lock R; Gorlick R; Kolb EA; Kurmasheva RT; Keir ST; Maris JM; Billups CA; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2013 May; 60(5):791-8. PubMed ID: 23002019
[TBL] [Abstract][Full Text] [Related]
16. Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts.
Birle DC; Hedley DW
Mol Cancer Ther; 2006 Oct; 5(10):2494-502. PubMed ID: 17041093
[TBL] [Abstract][Full Text] [Related]
17. Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program.
Houghton PJ; Morton CL; Gorlick R; Kolb EA; Keir ST; Reynolds CP; Kang MH; Maris JM; Wu J; Smith MA
Pediatr Blood Cancer; 2010 Jul; 54(7):921-6. PubMed ID: 20166202
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of entinostat alone and in combination with standard-of-care cytotoxic agents against rhabdomyosarcoma xenograft models.
Kurmasheva RT; Bandyopadhyay A; Favours E; Del Pozo V; Ghilu S; Phelps DA; Erickson SW; Peer CJ; Figg WD; Smith MA; Houghton PJ
Pediatr Blood Cancer; 2019 Aug; 66(8):e27820. PubMed ID: 31099166
[TBL] [Abstract][Full Text] [Related]
19. ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo.
Ackler S; Xiao Y; Mitten MJ; Foster K; Oleksijew A; Refici M; Schlessinger S; Wang B; Chemburkar SR; Bauch J; Tse C; Frost DJ; Fesik SW; Rosenberg SH; Elmore SW; Shoemaker AR
Mol Cancer Ther; 2008 Oct; 7(10):3265-74. PubMed ID: 18852130
[TBL] [Abstract][Full Text] [Related]
20. Targeting mTOR/p70S6K/glycolysis signaling pathway restores glucocorticoid sensitivity to 4E-BP1 null Burkitt Lymphoma.
Gu L; Xie L; Zuo C; Ma Z; Zhang Y; Zhu Y; Gao J
BMC Cancer; 2015 Jul; 15():529. PubMed ID: 26189041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
